+1-518-618-1030 866 - 552 - 3453 USA-Canada Toll Free
Published Date: 2012-06-18Number of Pages: 78

Asthma and COPD Drug Market - Global Industry Analysis, Market Size, Share, Trends, Growth and Forecasts 2010 - 2017

In the overall Asthma and COPD market, Advair remained the market leader with USD 7,802 million in 2011 and is expected to reach USD xxxx million in 2014. Singulair is the second largest drug in terms of revenue at UD 5479 million in 2011. The patent that provides U.S. market exclusivity for Singulair will expire in August 2012. It is expected that within 2-3 years following patent expiration, it will lose substantially all U.S. sales of Singulair, with most of those declines coming in the first full year following patent expiration. Also, the patent that provides market exclusivity for Singulair will expire in a number of major European markets in February 2013 and sales of Singulair in those markets will decline significantly thereafter. The patent that provides market exclusivity for Singulair in Japan will expire in 2016.


Asia Pacific region commanded for the largest share of global Asthma patients in 2010. The North America region will have the fastest growth rate for asthma patients at a CAGR of 3.9% in the world during 2010 - 2017. Globally, patients numbers are increasing continuously primarily due to cigarette smoking, continual exposure to hazardous particles or gases, increase in urbanization, change in lifestyle, and genetic factors. The growing number of asthmatics people from china and other economies will drive the revenue growth for the Asthma and COPD drugs market.


At present, long-acting beta2 agonist (LABA) / inhaled corticosteroid (ICS) combinations are the preferred combinations in the U.S. for treatment of asthma and/or COPD that include Advair (GlaxoSmithKline), Symbicort (AstraZeneca), and Dulera (Merck). LABA/ICS combinations are the most prescribed drugs because they offer efficacy and the convenience of delivering two drugs in one inhaler. The U.S. sales for asthma and COPD drugs are expected to total more than USDxxxx billion in 2012. 


In Europe, LABA / ICS combinations and LTA (Montelukast) drugs are more popular for asthma and COPD treatment. Merck's branded product Singulair contains Montelukast sodium, which is a leading oral anti-asthma and anti-allergy drug. Singulair is one of the trusted drugs for the treatment of chronic asthma, and for the relief of symptoms of seasonal allergic rhinitis. Currently, Montelukast is the largest selling anti-asthmatic drug worldwide.


For COPD patients, physicians also prescribe use of the long-acting muscarinic antagonist (LAMA) Spiriva (Boehringer Ingelheim/Pfizer).  Spiriva is expected to constitute about xxx% of the U.S. COPD drug sales in 2012. The LABA/LAMA combination is preferred for the treatment of COPD. Several combinations are in late-stage development, including vilanterol / GSK-573719 (GlaxoSmithKline/Theravance), indacaterol / glycopyrronium (Novartis), and olodaterol / tiotropium (Boehringer Ingelheim).


Key products exposed to generic competition include GlaxoSmithKline’s Advair Boehringer Ingelheim/Pfizer’s Spiriva and Merck’s Singulair, which will lose active ingredient patent protection in the U.S. in 2011 and 2012 respectively. Patent expiration of Merck’s Singulair, which generated sales of around USD 3.3 billion in 2010, will be a key restraint for the overall Asthma market as generic entry in the United States, Europe and Japan will reduce sales of branded Singulair.



Asthma is characterized by recurrent attacks of coughing, chest-tightening, breathlessness and wheezing as the airways narrow and swell that vary in severity and frequency. This chronic disease is most common among children.




Asthma and COPD Drug Market: Overview

The multi-billion dollar global asthma and chronic obstructive pulmonary disease (COPD) drugs market has been expanding at a steady pace, fueled primarily by the growing patient population. The World Health Organization estimates that in 2015, the number of deaths caused by COPD stood at 3 million. The organization also states that at present, there are around 235 million people suffering from asthma around the globe. While both asthma and COPD cannot be cured, the symptoms can be managed and controlled with the help of appropriate medication. These drugs not only help relieve symptoms, but also increase the patient’s exercise capacity and enable them to lead a better life.

This report is designed to guide clients in identifying the main areas of growth in the asthma and COPD drugs market and equip them with the right tools to face the challenges that lie ahead. Major opportunities have been highlighted and suggestions on how to overcome various hurdles have been discussed at length.

Asthma and COPD Drug Market: Trends and Opportunities

The global asthma and COPD drugs market is estimated to value US$26.9 bn by the end of 2017. Poor air quality in several emerging economies of the Middle East and Africa, Asia Pacific, and Latin America – such as India, China, Russia, and Brazil – has resulted in the increased prevalence of various respiratory diseases. This has upped the demand for and consumption of asthma and COPD drugs. Some of the other major factors driving the market are rising geriatric population, growing prevalence of asthma and chronic obstructive pulmonary disease, strong pipeline products, technological advancements, rising health awareness, greater spending on healthcare, and increasing government as well as non-government support and initiatives.

On the down side, certain side effects of asthma and COPD drugs, strict regulatory requirements for drug approvals, and patent expiry of blockbuster drugs threaten to keep this market from realizing its full potential. Be that as it may, developing countries have been providing immense opportunities for growth. The introduction of generic drugs by local and regional players in these countries will open new doors for companies looking to invest in and capitalize on the opportunities presented here.

Asthma and COPD Drug Market: Regional Outlook

North America accounts for a prominent share in the global market for asthma and COPD drugs, with the U.S. emerging as the clear leader. Higher patient awareness and increased prices of asthma and COPD drugs are the primary factors driving the U.S. market in terms of revenue. Strong pipeline studies and products also reflect positively on this market and indicates that the country-wide market will continue to play a major role in the development of the North America market for asthma and COPD drugs. A significant rise in initiatives by government and public bodies and growing investments made by them have also contributed toward the expansion of this market.

However, despite these strong factors in its favor, North America is projected to witness a decline in terms of market share owing to the immense potential of other emerging regional markets. The patent expiry of major blockbuster drugs by pharmaceutical companies based out of North America will also result in a drop in market share.

Asia Pacific continues to be a promising market for asthma and COPD drugs thanks primarily to the rising incidence of respiratory diseases. This can be attributed to alarming air pollution and increased population of smokers.

Companies mentioned in the report

Roche Holding AG (Switzerland), Vectura Group (U.K.), Teva Pharmaceutical Industries (Israel), Novartis AG (Switzerland), Boehringer Ingelheim (Germany), GlaxoSmithKline (GSK) (U.K.), Merck & Co. (U.S.), Abbott Laboratories (U.S.), Pfizer (U.S.), and AstraZeneca (U.K.) are some of the prominent companies operating in the global asthma and COPD drug market. Most players in the market have been focusing their capabilities on expanding in emerging economies owing to the immense opportunities available there. Development of innovative products through R&D and clinical trials is also a key growth strategy adopted by players in the asthma and COPD drugs market.

In the next five years, the global asthma and COPD drug market is expected to grow slowly, primarily because of expiry of patents of leading drug brands and price erosion in the market. However, by 2017, few novel drugs are expected to enter the asthma and COPD market, which will drive future growth. The existing asthma and COPD market is mainly driven by increasing patient population. The other factors that will drive the market include long term use of asthma and COPD drugs, increase in disposable income and improved access to medical care facilities in emerging economies. 


Competition in the asthma market is becoming intense due to the increased entry of combinational therapies, inhaled corticosteroids and beta-agonists. It is expected that Symbicort, Advair and Singulair would be the leading drugs of the global asthma and COPD market, while GlaxoSmithKline, AstraZeneca and Merck will continue to be the market leaders till the patents on their drugs expire in the coming years. 

The restraints in the asthma and COPD drug market is the threat of generic products in the market since many patents are going to expire in the coming years and governments have restrictions on healthcare budgets. The patent expiry of Merck’s Singulair in 2012 and Advairs’ in 2016 will shift the manufacturers to generic drugs. The purchasers will have high bargaining power due to large competition in the market and cost consciousness is expected to remain one of the major constraints in the COPD and asthma drug market.


The opportunities in the asthma and COPD market is huge as many companies are focusing on contract manufacturing outsourcing (CMO) and large players have entered this market with new product development. Increase in awareness about the benefits of timely diagnosis for asthma and COPD and availability of healthcare equipment for the detection of asthma and COPD in rural areas will further boost the market and growth opportunities for market players. 


In China, growth in urbanization and change in lifestyle has projected sharp increase in occurrence of asthma in the recent years. The occurrence of asthma symptoms is higher in urban areas as compared to rural areas. Air pollution and smoking are the most important factors which have led to the rapid increase in asthma and COPD patients in China.



Asthma and Chronic Obstructive Pulmonary Disease (COPD) are diseases that cause chest symptoms leading to coughing, difficulty in breathing and wheezing. Asthma impacts a patient during the night time whereas COPD affect during the day time. They can coexist in the same individual whereas the cause and treatment of both these symptoms are different. Asthma is caused majorly due to allergies whereas COPD is a result of smoking. Asthma leads to inflammation of lungs and COPD leads to destructive illness of lungs. 


The report contains the global scenario of Asthma and COPD market discussing detailed overview and market figures. The research report analyses the industry growth rate, industry capacity, and industry structure. The report analyses the historical data and forecasts the Asthma and COPD market size, production forecasts along with key factors driving and restraining the market


This research is specially designed to estimate and analyze the demand, performance and size of “Asthma and COPD” Market in China and Global scenario. The research will provide in-depth analysis of value chain, product sales, trend analysis and demand by geography. The study will present a comprehensive assessment of the stakeholders’ strategies and winning imperatives for them.


Our report gives you the following advantages:


  • Find revenue predictions to 2017 for the World and China Asthma and COPD market
  • Discover revenue forecasts to 2017 for leading products, assessing market potentials
  • Assess leading companies, and discover their revenue prospects in near future
  • See revenue forecasts to 2017 for leading markets - US, Europe, Asia and China
  • Review R&D for asthma and COPD, assessing potential
  • Investigate competition and opportunities influencing the industry and market
  • Growth drivers and restrain of the industry and market from 2012 onwards

Back To Top